WallStreetZenWallStreetZen

NYSE: BIO
Bio Rad Laboratories Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for BIO

Based on 2 analysts offering 12 month price targets for Bio Rad Laboratories Inc

Min Forecast
$340.00+13.51%
Avg Forecast
$357.50+19.35%
Max Forecast
$375.00+25.19%

Should I buy or sell BIO stock?

Based on 2 analysts offering ratings for Bio Rad Laboratories Inc.

Buy
Strong Buy
1 analysts 50%
Buy
0 analysts 0%
Hold
1 analysts 50%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their BIO stock forecasts and price targets.

BIO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-10-30Find Out Why
lockedlocked$00.00+00.00%2025-10-30

1 of 1

Forecast return on equity

Is BIO forecast to generate an efficient return?

Company
3.61%
Industry
27.28%
Market
218.22%
BIO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BIO forecast to generate an efficient return on assets?

Company
2.51%
Industry
14.71%
BIO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BIO earnings per share forecast

What is BIO's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$10.25
Avg 2 year Forecast
$11.38
Avg 3 year Forecast
$8.95

BIO revenue forecast

What is BIO's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$2.7B+4.13%
Avg 2 year Forecast
$2.8B+7.92%
Avg 3 year Forecast
$2.7B+6%
BIO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BIO revenue growth forecast

How is BIO forecast to perform vs Medical Devices companies and vs the US market?

Company
2.66%
Industry
9.53%
Market
22.77%
BIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BIO vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
BIO$305.90$357.50+16.87%Buy
MASI$136.62$189.75+38.89%Strong Buy
GKOS$114.67$132.10+15.20%Strong Buy
BRKR$42.56$52.67+23.75%Buy
ALGN$161.30$171.25+6.17%Buy
View Top Medical Device Stocks

Bio Rad Laboratories Stock Forecast FAQ

Is Bio Rad Laboratories Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NYSE: BIO) stock is to Buy BIO stock.

Out of 2 analysts, 1 (50%) are recommending BIO as a Strong Buy, 0 (0%) are recommending BIO as a Buy, 1 (50%) are recommending BIO as a Hold, 0 (0%) are recommending BIO as a Sell, and 0 (0%) are recommending BIO as a Strong Sell.

If you're new to stock investing, here's how to buy Bio Rad Laboratories stock.

What is BIO's earnings growth forecast for 2026-2028?

(NYSE: BIO) Bio Rad Laboratories's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 17.83%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.92%.

Bio Rad Laboratories's earnings in 2026 is -$675,902,000.On average, 7 Wall Street analysts forecast BIO's earnings for 2026 to be $276,510,941, with the lowest BIO earnings forecast at $217,827,188, and the highest BIO earnings forecast at $307,594,044. On average, 6 Wall Street analysts forecast BIO's earnings for 2027 to be $306,838,748, with the lowest BIO earnings forecast at $230,251,797, and the highest BIO earnings forecast at $352,062,059.

In 2028, BIO is forecast to generate $241,387,008 in earnings, with the lowest earnings forecast at $234,217,097 and the highest earnings forecast at $250,946,890.

What is BIO's revenue growth forecast for 2026-2028?

(NYSE: BIO) Bio Rad Laboratories's forecast annual revenue growth rate of 2.66% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.55%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.81%.

Bio Rad Laboratories's revenue in 2026 is $2,557,475,000.On average, 7 Wall Street analysts forecast BIO's revenue for 2026 to be $71,833,985,605, with the lowest BIO revenue forecast at $68,435,156,395, and the highest BIO revenue forecast at $76,149,959,205. On average, 6 Wall Street analysts forecast BIO's revenue for 2027 to be $74,450,544,600, with the lowest BIO revenue forecast at $69,675,998,805, and the highest BIO revenue forecast at $78,658,618,860.

In 2028, BIO is forecast to generate $73,128,777,685 in revenue, with the lowest revenue forecast at $70,970,790,885 and the highest revenue forecast at $76,042,059,865.

What is BIO's forecast return on assets (ROA) for 2026-2029?

(NYSE: BIO) forecast ROA is 2.51%, which is lower than the forecast US Medical Devices industry average of 14.69%.

What is BIO's Price Target?

According to 2 Wall Street analysts that have issued a 1 year BIO price target, the average BIO price target is $357.50, with the highest BIO stock price forecast at $375.00 and the lowest BIO stock price forecast at $340.00.

On average, Wall Street analysts predict that Bio Rad Laboratories's share price could reach $357.50 by Oct 30, 2026. The average Bio Rad Laboratories stock price prediction forecasts a potential upside of 16.87% from the current BIO share price of $305.90.

What is BIO's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: BIO) Bio Rad Laboratories's current Earnings Per Share (EPS) is -$24.21. On average, analysts forecast that BIO's EPS will be $10.25 for 2026, with the lowest EPS forecast at $8.08, and the highest EPS forecast at $11.40. On average, analysts forecast that BIO's EPS will be $11.38 for 2027, with the lowest EPS forecast at $8.54, and the highest EPS forecast at $13.05. In 2028, BIO's EPS is forecast to hit $8.95 (min: $8.68, max: $9.30).

What is BIO's forecast return on equity (ROE) for 2026-2029?

(NYSE: BIO) forecast ROE is 3.61%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.